Evidence map›Paper›PMID 35314687›Full record

ArticleNature communications2022

Siwi cooperates with Par-1 kinase to resolve the autoinhibitory effect of Papi for Siwi-piRISC biogenesis.

Hiromi Yamada, Kazumichi M Nishida, Yuka W Iwasaki, Yosuke Isota, Lumi Negishi, Mikiko C Siomi

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hiromi YamadaDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, 113-0032, Japan.
Kazumichi M NishidaDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, 113-0032, Japan.
Yuka W IwasakiDepartment of Molecular Biology, Keio University School of Medicine, Tokyo, 162-8582, Japan.ORCID 0000-0002-2182-2076
Yosuke IsotaDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, 113-0032, Japan.
Lumi NegishiCentral Laboratory, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, 113-0032, Japan.
Mikiko C SiomiDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, 113-0032, Japan. siomim@bs.s.u-tokyo.ac.jp.ORCID 0000-0002-6149-4396
The University of Tokyo · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bombyx Papi acts as a scaffold for Siwi-piRISC biogenesis on the mitochondrial surface. Papi binds first to Siwi via the Tudor domain and subsequently to piRNA precursors loaded onto Siwi via the K-homology (KH) domains. This second action depends on phosphorylation of Papi. However, the underlying mechanism remains unknown. Here, we show that Siwi targets Par-1 kinase to Papi to phosphorylate Ser547 in the auxiliary domain. This modification enhances the ability of Papi to bind Siwi-bound piRNA precursors via the KH domains. The Papi S547A mutant bound to Siwi, but evaded phosphorylation by Par-1, abrogating Siwi-piRISC biogenesis. A Papi mutant that lacked the Tudor and auxiliary domains escaped coordinated regulation by Siwi and Par-1 and bound RNAs autonomously. Another Papi mutant that lacked the auxiliary domain bound Siwi but did not bind piRNA precursors. A sophisticated mechanism by which Siwi cooperates with Par-1 kinase to promote Siwi-piRISC biogenesis was uncovered.

Indexed as

BombyxAnimalsRNA, Small InterferingTudor DomainRNA, Small Interfering

Identifiers

PMID35314687
PMCPMC8938449
OpenAlexW4220841327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.